The life sciences sector as a whole is looking for collaboration opportunities that build on the technologies, platforms and ways of working that have proven their mettle through the pandemic. These developments will create new products and services that could vastly improve patient care and outcomes across a range of conditions.

Based on a survey of 100 senior-level US-based executives at life sciences companies, this report explores how the stage appears to be set for more and faster breakthroughs than ever before.

Key findings include: 

• For buyers, the top reason for their most recent acquisition was diversifying their product portfolio (for reasons other than patent expiration), while for sellers it was to broaden their customer base.
• The most important reasons for buyers to have formed a partnership over the past 18 months are gaining access to a partner’s particular capabilities and resources without having to deal with parts of the business extraneous to the company’s strategy (23%), as well as forming connections with other organizations for potential new partnerships in the future (also 23%).
• With more experience doing deals during the pandemic, just 25% of respondents this year say they made changes to their typical post-closing integration process in light of the COVID-19 crisis, down noticeably from the 36% who reported the same in last year’s research.